Johnson&Johnson Opsynvi single tablet combination therapy approved by FDA
我放心你带套猛
发表于 2024-3-23 17:13:08
227
0
0
Johnson&Johnson announced on the 23rd that the US FDA has approved its Opsynvi monotherapy combination therapy for long-term treatment of adult patients with pulmonary arterial hypertension (PAH) classified as II-III by the World Health Organization (WHO) Functional Classification (FC). The approval of Opsynvi enables Johnson&Johnson's PAH product portfolio to cover all PAH targeted pathways recommended by the guidelines. It is reported that Opsynvi is the first FDA approved PAH single tablet combination therapy. The approval of Opsynvi by the US FDA is mainly based on the results of key Phase 3 clinical studies of A DUE, in which Opsynvi demonstrates that patients have a greater reduction in pulmonary vascular resistance (PVR) after 16 weeks of treatment compared to monotherapy with tadalafil or macitabine.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Exploring the "Golden Nine Silver Ten" in the Car Market: Car Companies Play a Promotion Combination Fist, and New Energy Sales Continuously Rise
- Argentina's economic experiment is about to take place! Today, the global market will witness the impact of "shock therapy"
- AstraZeneca will acquire Genxi Biotechnology to deepen the layout of cell therapy in the fields of tumors and autoimmune diseases
- 12 weeks of weight loss exceeding 13%. Novo Nordisk's oral therapy has been declared clinically in China
- Baishime Squibb CAR-T therapy approved by the US FDA
- GSK is betting 1.45 billion euros on the imminent outbreak of cross generational business opportunities in mRNA therapy categories?
- Modner claims that the company has reached a joint agreement with Mitsubishi Tanabe Pharmaceuticals to promote the company's mRNA respiratory vaccine portfolio in Japan
- Is the beef fillet at the small ingredient counter gone? Haidilao: Free selection available on tablets
- Huang Xiaoyi, Managing Director of Fidelity International China: The policy combination has brought tremendous confidence to the market | Foreign experts talk ⑥
- Eli Lilly's Alzheimer's disease treatment with donentinumab injection approved
-
隔夜株式市場 世界の主要指数は金曜日に多くが下落し、最新のインフレデータが減速の兆しを示したおかげで、米株3大指数は大幅に回復し、いずれも1%超上昇した。 金曜日に発表されたデータによると、米国の11月のPC ...
- SNT
- 前天 12:48
- 支持
- 反对
- 回复
- 收藏
-
長年にわたって、昔の消金大手の捷信消金の再編がようやく地に着いた。 天津銀行の発表によると、同行は京東傘下の2社、対外貿易信託などと捷信消金再編に参加する。再編が完了すると、京東の持ち株比率は65%に達し ...
- SNT
- 前天 12:09
- 支持
- 反对
- 回复
- 收藏
-
【GPT-5屋台で大きな問題:数億ドルを燃やした後、OpenAIは牛が吹くのが早いことを発見した】OpenAIのGPT-5プロジェクト(Orion)はすでに18カ月を超える準備をしており、関係者によると、このプロジェクトは現在進 ...
- SNT
- 5 小时前
- 支持
- 反对
- 回复
- 收藏
-
【ビットコインが飛び込む!32万人超の爆倉】データによると、過去24時間で世界には32万7000人以上の爆倉があり、爆倉の総額は10億ドルを超えた。
- 断翅小蝶腥
- 3 天前
- 支持
- 反对
- 回复
- 收藏